Home / Health / Amgen: Low LDL Levels With Repatha Did Not Affect Cognitive Function In Study

Amgen: Low LDL Levels With Repatha Did Not Affect Cognitive Function In Study

Shutterstock photo

(RTTNews.com) – Amgen Inc. ( AMGN ) announced formula from a Repatha or evolocumab cognitive duty hearing (EBBINGHAUS) evaluating a impact on cognitive duty in 1,974 patients enrolled in a Repatha cardiovascular outcomes study, FOURIER.

The investigate demonstrated that a outcome of Repatha on a primary endpoint of executive duty was non-inferior to placebo.

In addition, Amgen remarkable that there was no statistical disproportion between Repatha and remedy on a other cognitive domains tested: operative memory, memory duty and psychomotor speed – a delegate endpoints.

Amgen presented a minute formula from EBBINGHAUS during a Late-Breaking Clinical Trials Session during a American College of Cardiology 66th Annual Scientific Session in Washington, D.C.

For comments and feedback: hit editorial@rttnews.com

http://www.rttnews.com






Article source: http://www.nasdaq.com/article/amgen-low-ldl-levels-with-repatha-did-not-affect-cognitive-function-in-study-20170318-00013

InterNations.org

Leave a Reply

Your email address will not be published. Required fields are marked *

*


*